{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:21:29Z","timestamp":1792081289874,"version":"4.4.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejca.2022.08.016","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T19:40:25Z","timestamp":1663789225000},"page":"214-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-9242","authenticated-orcid":false,"given":"C. Mircea S.","family":"Tesileanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies R.","family":"Vallentgoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-9529","authenticated-orcid":false,"given":"Pim J.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5127","authenticated-orcid":false,"given":"Martin J.","family":"van den Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.08.016_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2022.08.016_bib2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41419-021-04146-0","article-title":"The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma","volume":"12","author":"Ahmadov","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejca.2022.08.016_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/neuonc\/not227","article-title":"Clinical value of chromosome arms 19q and\u00a011p losses in low-grade gliomas","volume":"16","author":"Alentorn","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib5","first-page":"vdaa042","article-title":"Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1","volume":"2","author":"Alghamri","year":"2020","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ejca.2022.08.016_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/neuonc\/nox132","article-title":"Prognostic relevance of genetic alterations in diffuse lower-grade gliomas","volume":"20","author":"Aoki","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/neuonc\/noz126.000","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00401-019-02067-z","article-title":"FOCAD loss impacts microtubule assembly, G2\/M progression and patient survival in astrocytic gliomas","volume":"139","author":"Brand","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2022.08.016_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.humpath.2018.04.024","article-title":"Overexpression of MCM6 predicts poor survival in patients with glioma","volume":"78","author":"Cai","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2022.08.016_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2022.08.016_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12935-019-0867-1","article-title":"Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma","volume":"19","author":"Chai","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ejca.2022.08.016_bib12","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/carcin\/bgz102","article-title":"Systematically characterize the clinical and biological significances of 1p19q genes in 1p\/19q non-codeletion glioma","volume":"40","author":"Chai","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2022.08.016_bib13","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1007\/s12035-016-0150-6","article-title":"Gene expression profiling stratifies IDH1-mutant glioma with distinct prognoses","volume":"54","author":"Cheng","year":"2017","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.ejca.2022.08.016_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-016-2368-6","article-title":"Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1\/2 status","volume":"132","author":"Cheng","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19102903","article-title":"Identification of a prognostic hypoxia-associated gene set in IDH-mutant glioma","volume":"19","author":"Dao Trong","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2022.08.016_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112756","article-title":"Association of circadian clock gene expression with glioma tumor microenvironment and patient survival","volume":"13","author":"De La Cruz Minyety","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ejca.2022.08.016_bib17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.celrep.2018.03.107","article-title":"A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence","volume":"23","author":"de Souza","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2022.08.016_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s40478-015-0265-4","article-title":"PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients","volume":"3","author":"Draaisma","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ejca.2022.08.016_bib19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s13402-021-00612-1","article-title":"A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing","volume":"44","author":"Fan","year":"2021","journal-title":"Cell Oncol (Dordr)."},{"key":"10.1016\/j.ejca.2022.08.016_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3171\/2017.9.JNS172036","article-title":"Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma","volume":"130","author":"Karsy","year":"2018","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2022.08.016_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/nan.12523","article-title":"Integrated molecular characterization of IDH-mutant glioblastomas","volume":"45","author":"Korshunov","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.ejca.2022.08.016_bib22","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2016-0003","article-title":"Chromosome 17p homodisomy is associated with better outcome in 1p19q non-codeleted and IDH-mutated gliomas","volume":"21","author":"Labussiere","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2022.08.016_bib23","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12070","article-title":"Prognostic\u00a0impact of a lymphocyte activation-associated gene signature in GBM based on transcriptome analysis","volume":"9","author":"Lan","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.ejca.2022.08.016_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00432-020-03132-x","article-title":"A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level","volume":"146","author":"Liu","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40478-019-0746-y","article-title":"Total copy number variation as a prognostic factor in adult astrocytoma subtypes","volume":"7","author":"Mirchia","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ejca.2022.08.016_bib26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/NEN.0b013e31825f2e5d","article-title":"DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome","volume":"71","author":"Motomura","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.ejca.2022.08.016_bib27","doi-asserted-by":"crossref","first-page":"84729","DOI":"10.18632\/oncotarget.20951","article-title":"Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain","volume":"8","author":"Nakae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.08.016_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1750-3639.2012.00609.x","article-title":"MET gain in diffuse astrocytomas is associated with poorer outcome","volume":"23","author":"Pierscianek","year":"2013","journal-title":"Brain Pathol"},{"key":"10.1016\/j.ejca.2022.08.016_bib29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/NEN.0000000000000188","article-title":"CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas","volume":"74","author":"Reis","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.ejca.2022.08.016_bib30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jnen\/nlab008","article-title":"Molecular signatures of chromosomal instability correlate with copy number variation patterns and patient outcome in IDH-mutant and IDH-wildtype astrocytomas","volume":"80","author":"Richardson","year":"2021","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.ejca.2022.08.016_bib31","doi-asserted-by":"crossref","first-page":"72431","DOI":"10.18632\/oncotarget.11957","article-title":"PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status","volume":"7","author":"Roodakker","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.08.016_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","article-title":"Novel, improved grading system(s) for IDH-mutant astrocytic gliomas","volume":"136","author":"Shirahata","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2022.08.016_bib33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00401-021-02291-6","article-title":"Non-IDH1-R132H IDH1\/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations","volume":"141","author":"Tesileanu","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2022.08.016_bib34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/neuonc\/noab088","article-title":"Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p\/19q deleted anaplastic glioma","volume":"23","author":"Tesileanu","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.605737","article-title":"A novel four-gene signature associated with immune checkpoint for predicting prognosis in lower-grade glioma","volume":"10","author":"Xiao","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib36","article-title":"Abnormal expression of HOXD11 promotes the malignant behavior of glioma cells and leads to poor prognosis of glioma patients","volume":"9","author":"Wang","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.ejca.2022.08.016_bib37","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00262-021-03058-4","article-title":"Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival","volume":"71","author":"Wang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2022.08.016_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.1609825","article-title":"Clinical value of TXNDC12 combined with IDH and 1p19q as biomarkers for prognosis of glioma","volume":"27","author":"Wang","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ejca.2022.08.016_bib39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-018-2867-8","article-title":"Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma","volume":"139","author":"Wijnenga","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib40","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41379-021-00778-x","article-title":"Molecular landscape of IDH-mutant primary astrocytoma Grade IV\/glioblastomas","volume":"34","author":"Wong","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2022.08.016_bib41","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/carcin\/bgz032","article-title":"Molecular classification of IDH-mutant glioblastomas based on gene expression profiles","volume":"40","author":"Wu","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2022.08.016_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12935-018-0603-2","article-title":"Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma","volume":"18","author":"Wu","year":"2018","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ejca.2022.08.016_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1515\/biol-2021-0039","article-title":"TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation","volume":"16","author":"Yuan","year":"2021","journal-title":"Open Life Sci"},{"key":"10.1016\/j.ejca.2022.08.016_bib44","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12935-018-0695-8","article-title":"ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2(Q607R)","volume":"18","author":"Zhang","year":"2018","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ejca.2022.08.016_bib45","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41419-021-04427-8","article-title":"Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejca.2022.08.016_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164117","article-title":"Algorithmically deduced FREM2 molecular pathway is a potent grade and survival biomarker of human gliomas","volume":"13","author":"Zolotovskaia","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.08.016_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/genes11070824","article-title":"P14(ARF): the absence that makes the difference","volume":"11","author":"Cilluffo","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ejca.2022.08.016_bib48","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 inhibition in cancer: beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.ejca.2022.08.016_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mam.2017.11.007","article-title":"The PDGF\/PDGFR pathway as a drug target","volume":"62","author":"Papadopoulos","year":"2018","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.ejca.2022.08.016_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920207782446160","article-title":"The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications","volume":"8","author":"Arcaro","year":"2007","journal-title":"Curr Genomics"},{"key":"10.1016\/j.ejca.2022.08.016_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2019.03.006","article-title":"Receptor tyrosine kinases in PI3K signaling: the therapeutic targets in cancer","volume":"59","author":"Jiang","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejca.2022.08.016_bib52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2022.08.016_bib53","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1101\/gad.12.15.2245","article-title":"The regulation of E2F by pRB-family proteins","volume":"12","author":"Dyson","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejca.2022.08.016_bib54","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0955-0674(99)00044-7","article-title":"How do small GTPase signal transduction pathways regulate cell cycle entry?","volume":"11","author":"Marshall","year":"1999","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.ejca.2022.08.016_bib55","first-page":"F115","article-title":"The p16INK4a\/CDKN2A tumor suppressor and its relatives","volume":"1378","author":"Ruas","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2022.08.016_bib56","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1042\/BST20140070","article-title":"PI3K\/Akt-mediated regulation of p53 in cancer","volume":"42","author":"Abraham","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ejca.2022.08.016_bib57","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","article-title":"Regulation of cell death protease caspase-9 by phosphorylation","volume":"282","author":"Cardone","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejca.2022.08.016_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc.2015.4","article-title":"DNA repair, genome stability and cancer: a historical perspective","volume":"16","author":"Jeggo","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2022.08.016_bib59","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.21037\/atm-20-2920","article-title":"Alterations of DNA damage repair in cancer: from mechanisms to applications","volume":"8","author":"Jiang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejca.2022.08.016_bib60","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability--an evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ejca.2022.08.016_bib61","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/15384101.2018.1456296","article-title":"Diverse roles of RAD18 and Y-family DNA polymerases in tumorigenesis","volume":"17","author":"Yang","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejca.2022.08.016_bib62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41419-022-04751-7","article-title":"Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression","volume":"13","author":"Hanisch","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejca.2022.08.016_bib63","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1038\/s41598-022-09614-x","article-title":"Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma","volume":"12","author":"Ganesa","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2022.08.016_bib64","first-page":"21","article-title":"Mismatch-repair protein expression in high-grade gliomas: a large retrospective multicenter study","author":"Caccese","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2022.08.016_bib65","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","article-title":"Molecular pathways: isocitrate dehydrogenase mutations in cancer","volume":"22","author":"Clark","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.08.016_bib66","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.08.016_bib67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.08.016_bib68","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nature09303","article-title":"Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification","volume":"466","author":"Ito","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.08.016_bib69","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ejca.2022.08.016_bib70","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrm2950","article-title":"Active DNA demethylation: many roads lead to Rome","volume":"11","author":"Wu","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ejca.2022.08.016_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-5960-2-19","article-title":"D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma","volume":"2","author":"Pusch","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ejca.2022.08.016_bib72","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/neuonc\/nox183","article-title":"Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications","volume":"20","author":"Malta","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.08.016_bib73","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2009.06.001","article-title":"CTCF: master weaver of the genome","volume":"137","author":"Phillips","year":"2009","journal-title":"Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922005032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922005032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:39Z","timestamp":1760733519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922005032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":73,"alternative-id":["S0959804922005032"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.08.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}